Clinical Trial Update: MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma [Phase 2]

View source ↗

Summary

Phase 2 trial updates on MEDI4736 (durvalumab) alone or with tremelimumab in surgically resectable malignant pleural mesothelioma have completed with results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Mesothelioma

Drugs mentioned

• MEDI4736 (Durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Baylor College of Medicine | Conditions: Mesothelioma | Phase 2 | Status: COMPLETED | Results posted: 2022-01-13